Alan Nicolle

Alan Nicolle’s background includes work across the fields of consultancy, global CROs, and big pharmaceutical companies before he joined MMS in 2014.

In his current position, Alan is responsible for the strategic leadership and planning of the operational side of the business. His main focus revolves around supporting and developing strategic initiatives, overseeing special projects that are of key importance, and assisting the COO with the creation of both short-term and long-term business goals. Alan collaborates closely with executive leadership and heads of all service lines to ensure alignment with the company’s key priorities. Additionally, he provides support to HR and finance functions when needed, aiming to maintain a successful business operational structure within various global regions.

Alan holds a Postgraduate Diploma in Information Technology and Society, as well as a Bachelor’s degree in Physiology and Biochemistry from the University of Southampton.

Suggested For You

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success